期刊文献+

肝素诱导血小板减少症一例的循证治疗 被引量:3

原文传递
导出
摘要 肝素诱导血小板减少症(HIT)是一种由肝素引起的、免疫介导的严重并发症,一般在应用肝素后5~14d发生,以血小板减少和血栓形成为主要特征。停止肝素后血栓的发生率仍然高达38%~76%,静脉系统血栓的发生率约为动脉系统的4倍,病死率高达20%~30%,因卒中和截肢导致的致残率为20%~30%。采取恰当的治疗方案对改善预后至关重要。
出处 《中华内科杂志》 CAS CSCD 北大核心 2007年第8期678-680,共3页 Chinese Journal of Internal Medicine
  • 相关文献

参考文献5

  • 1Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med, 1996, 101:502-507. 被引量:1
  • 2Lubenow N, Eichler P, Lietz T, et al. Lepirudin in patients with heparin-indueed thromboeytopenia-results of the third prospective study ( HAT-3 ) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost, 2005, 3:2428-2436. 被引量:1
  • 3LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med, 2004, 32:976-980. 被引量:1
  • 4Warkentin TE, Greinacher A. Heparin-indueed thrombocytopenia: Recognition, treatment, and prevention : The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 126:311S-337S. 被引量:1
  • 5Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol, 2006, 18 : 162-164. 被引量:1

同被引文献42

  • 1Gurbuz AT, Elliott WG, Zia AA. Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines. Eur J Cardiothorac Surg, 2005,27: 138- 149. 被引量:1
  • 2Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother,2006,40 : 1383-1387. 被引量:1
  • 3Gao C, Boylan B, Fang J, et al. Heparin promotes platelet responsiveness by potentiating cdIb133-mediated outside-in signaling. Blood ,2011,117:4946-4952. 被引量:1
  • 4Chong BH. Heparin-indueed thrombocytopenia. J Thromb Haemost ,2003,1 : 1471-1478. 被引量:1
  • 5Pollak ES, Abrams CS. Clinical presentation and laboratory diagnosis of heparin-indueed thromboeytopenia. Semin Thorae Cardiovasc Surg, 2005,17:80-84. 被引量:1
  • 6Greinacher A, Kohlmann T, Strobel U, et al. The temporal profile of the anti-PF4/heparin immune response. Blood, 2009, 113: 4970-4976. 被引量:1
  • 7Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest ,2012,141 (2 Suppl) : e495S-530S. 被引量:1
  • 8Chong BH, Gallus ASI Cade JF, et al. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis : a clinical outcome study. Thromb Haemost ,2001,86 : 1170-1175. 被引量:1
  • 9Ahmed I, Majeed A, Powell R. Heparin induced thromboeytopenia: diagnosis and management update. Postgrad Med J, 2007,83:575-582. 被引量:1
  • 10Smythe MA, Mehta TP, Koerber JM. Development and implementation of a comprehensive heparin-induced thrombocytopenia recognition and management protocol.Am J Health Syst Pharm, 2012,69:241-248. 被引量:1

引证文献3

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部